SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$99.04
−0.23%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -65.6%
- EBIT
- -17.1%
- EPS
- —
- Free cash flow
- -54.0%
- Operating cash flow
- -54.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -21.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -0.8%
- EBIT
- -0.5%
- Net income
- +25.4%
- EPS
- +37.7%
- Free cash flow
- -7.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026